Immune Therapeutics, Inc. (105) | Business Finance (23)
Browse by Subcategory
Recent Contracts
-
Convertible Promissory Note in the Principal Amount of $100,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps
(Filed With SEC on July 22, 2022)
-
Convertible Promissory Note in the Principal Amount of $100,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps
(Filed With SEC on July 22, 2022)
-
Convertible Promissory Note in the Principal Amount of $200,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps
(Filed With SEC on July 22, 2022)
-
Term Sheet
(Filed With SEC on July 7, 2022)
-
Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation
(Filed With SEC on March 18, 2022)
-
Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation
(Filed With SEC on March 18, 2022)
-
Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey
(Filed With SEC on March 18, 2022)
-
Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation
(Filed With SEC on March 18, 2022)
-
Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey
(Filed With SEC on March 18, 2022)
-
Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation
(Filed With SEC on May 24, 2021)
-
Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation
(Filed With SEC on May 24, 2021)
-
Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey
(Filed With SEC on May 24, 2021)
-
Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation
(Filed With SEC on May 24, 2021)
-
Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey
(Filed With SEC on May 24, 2021)
-
Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39
(Filed With SEC on April 15, 2021)
-
Amendment to the Articles of Incorporation filed February 5, 2020 approving a reverse split of issued and outstanding shares of common stock by 1,000 to 1
(Filed With SEC on August 14, 2020)
-
Amendment to the Articles of Incorporation filed March 12, 2020 approving an increase in authorized shares of common stock from 500,000,000 to 750,000,000
(Filed With SEC on August 14, 2020)
-
Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39
(Filed With SEC on May 14, 2020)
-
Convertible Promissory Note dated March 30, 2020 to Redstart Holdings Corp. in the principal amount of $53,000
(Filed With SEC on May 14, 2020)
-
Mutual Release and Non-Disparagement Agreement effective April 30, 2020
(Filed With SEC on May 5, 2020)
-
Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39
(Filed With SEC on May 20, 2019)
-
Letter to Shareholders
(Filed With SEC on May 15, 2019)
-
Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39
(Filed With SEC on April 16, 2019)